Results 21 to 30 of about 17,302 (216)

MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777)

open access: yes, 2021
Pevonedistat, an investigational, first-in-class NEDD8-activating enzyme inhibitor, disrupts protein homeostasis, leading to cancer cell death. For patients with higher-risk MDS ineligible for transplant, real-world data reveal median overall survival ...
Zeidner, Joshua   +35 more
core   +1 more source

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis

open access: yesNeoplasia: An International Journal for Oncology Research, 2021
During progression of myeloid neoplasms, the basophil compartment may expand substantially and in some of these patients, a basophilic leukemia is diagnosed.
Daniela Berger   +16 more
doaj   +1 more source

A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions

open access: yesCase Reports in Hematology, 2014
Therapy for acute leukemia in Jehovah’s Witnesses patients is very challenging because of their refusal to accept blood transfusions, a fundamental supportive therapy for this disease.
Yumi Yamamoto   +3 more
doaj   +1 more source

Thrombocytopenia between azacitidine monotherapy vs low-dose cytarabine monotherapy.

open access: yes, 2022
Thrombocytopenia between azacitidine monotherapy vs low-dose cytarabine monotherapy.
Romina Brignardello-Petersen (814592)   +7 more
core   +1 more source

Anemia events between azacitidine monotherapy vs low-dose cytarabine monotherapy.

open access: yes, 2022
Anemia events between azacitidine monotherapy vs low-dose cytarabine monotherapy.
Romina Brignardello-Petersen (814592)   +7 more
core   +1 more source

Neutropenia events between azacitidine monotherapy vs low-dose cytarabine monotherapy.

open access: yes, 2022
Neutropenia events between azacitidine monotherapy vs low-dose cytarabine monotherapy.
Romina Brignardello-Petersen (814592)   +7 more
core   +1 more source

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

open access: yesBMC Cancer, 2017
Background Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading ...
John F. Seymour   +20 more
doaj   +1 more source

Overall survival between azacitidine monotherapy vs low-dose cytarabine monotherapy.

open access: yes, 2022
Overall survival between azacitidine monotherapy vs low-dose cytarabine monotherapy.
Romina Brignardello-Petersen (814592)   +7 more
core   +1 more source

Development and Validation of a New Storage Procedure to Extend the In-Use Stability of Azacitidine in Pharmaceutical Formulations

open access: yesPharmaceuticals, 2021
Stability studies performed by the pharmaceutical industry are principally designed to fulfill licensing requirements. Thus, post-dilution or post-reconstitution stability data are frequently limited to 24 h only for bacteriological reasons, regardless ...
Antonella Iudicello   +4 more
doaj   +1 more source

Unveiling the Complete Biosynthetic Pathway of Azacitidine: A Rare 1,3,5‐Triazine Nucleoside Derived From GTP

open access: yesAngewandte Chemie, EarlyView.
The azacitidine biosynthetic gene cluster (aza BGC) was identified by the resistance‐gene‐guided comparative genomics method in Streptomyces mobaraensis IPIO2. The complete biosynthetic pathway of azacitidine, which follows a “base‐first‐then‐glycosylation” logic, was elucidated through in vivo and in vitro experiments.
Dan Wang   +6 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy